SSB-2548 抑制CXCR-4激活,诱导急性髓性白血病细胞中的亡
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Biotechnology and applied biochemistry
|February 18, 2025
概括
一种新型化合物,SSB-2548,有效地向急性髓性白血病 (AML) 细胞中的C-X-C化学因子受体4型 (CXCR-4). 这种CXCR-4抑制剂减少AML细胞的增殖和迁移,提供了一个有前途的新疗法策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 计算化学的计算化学
背景情况:
- 4型C-X-C化学因子受体 (CXCR-4) 在急性髓性白血病 (AML) 的进展和化疗耐药性方面发挥着关键作用.
- 准CXCR-4为新型AML疗法提供了潜在的战略.
研究的目的:
- 在AML细胞中选和识别抑制CXCR-4的化合物.
- 评估已识别的化合物对AML的治疗潜力.
主要方法:
- 使用AutoDock-Vina.com对大约85万个化合物的虚拟选.
- 使用GROMACS进行分子动力学模拟,以评估结合稳定性.
- 在体外测定使用AML细胞系 (THP-1,HL-60,SKM-1) 来测量增殖,亡和跨内皮移动.
- 使用瑞士ADME预测的吸收,分布,新陈代谢和分泌 (ADME) 特性.
主要成果:
- 确定SSB-2548是具有稳定结合CXCR-4的主要候选物.
- SSB-2548显示出AML细胞增殖的显著抑制 (GI50值在41.30至120.50nm之间).
- 该化合物减少了跨内皮细胞迁移,降低了CXCR-4表达,并在AML细胞中诱导了亡.
- 根据ADME的预测,SSB-2548.8具有有利的药理动力学特性和低毒性.
结论:
- SSB-2548是一种新型CXCR-4抑制剂,具有强大的抗AML活性.
- 该化合物有效地针对AML进展和耐药性的关键机制.
- SSB-2548显示出作为开发向AML治疗的候选人的承诺.
相关概念视频
The Intrinsic Apoptotic Pathway
6.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.1K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


